Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2013 Jan 24

PMID 23340324

Citations 13

Authors

A Seda Yilmaz-Elis

Annemieke Aartsma-Rus

Peter Ac t Hoen

Huma Safdar

Cor Breukel

Bart Jm van Vlijmen

Judith van Deutekom

Sjef de Kimpe

Gert-Jan van Ommen

J Sjef Verbeek

Affiliations

Soon will be listed here.

Abstract

The cytokine interleukin 1(IL-1) initiates a wide range of proinflammatory cascades and its inhibition has been shown to decrease inflammation in a variety of diseases. IL-1 receptor accessory protein (IL-1RAcP) is an indispensible part of the IL-1R complex that stabilizes IL-1/IL-1R interaction and plays an important role in the signal transduction of the receptor complex. The soluble form of IL-1RAcP (sIL-1RAcP) contains only the extracellular domain and serves as a natural inhibitor of IL-1 signaling. Therefore, increasing sIL-1RAcP levels might be an attractive therapeutic strategy to inhibit IL-1-driven inflammation. To achieve this we designed specific antisense oligonucleotides (AON), to redirect pre-mRNA IL-1RAcP splicing by skipping of the transmembrane domain encoding exon 9. This would give rise to a novel Δ9IL-1RAcP mRNA encoding a soluble, secreted form of IL-1RAcP, which might have similar activity as natural sIL-1RAcP. AON treatment resulted in exon 9 skipping both in vitro and in vivo. A single dose injection of 10 mg AON/kg body weight induced 90% skipping in mouse liver during at least 5 days. The truncated mRNA encoded for a secreted, soluble Δ9IL-1RAcP protein. IL-1RAcP skipping resulted in a substantial inhibition of IL-1 signaling in vitro. These results indicate that skipping of the transmembrane encoding exon 9 of IL-1RAcP using specific AONs might be a promising therapeutic strategy in a variety of chronic inflammatory diseases.Molecular Therapy - Nucleic Acids (2013) 2, e66; doi:10.1038/mtna.2012.58; published online 22 January 2013.

Citing Articles

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.

Gagliardi M, Tari Ashizawa A Biomedicines. 2021; 9(4).

PMID: 33923688 PMC: 8072990. DOI: 10.3390/biomedicines9040433.

Construction of a tri-chromatic reporter cell line for the rapid and simple screening of splice-switching oligonucleotides targeting DMD exon 51 using high content screening.

Shimo T, Tachibana K, Obika S PLoS One. 2018; 13(5):e0197373.

PMID: 29768479 PMC: 5955590. DOI: 10.1371/journal.pone.0197373.

Alternative pre-mRNA splicing of Toll-like receptor signaling components in peripheral blood mononuclear cells from patients with ARDS.

Blumhagen R, Hedin B, Malcolm K, Burnham E, Moss M, Abraham E Am J Physiol Lung Cell Mol Physiol. 2017; 313(5):L930-L939.

PMID: 28775099 PMC: 5792175. DOI: 10.1152/ajplung.00247.2017.

Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.

Pires V, Simoes R, Mamchaoui K, Carvalho C, Carmo-Fonseca M PLoS One. 2017; 12(7):e0181065.

PMID: 28742140 PMC: 5524367. DOI: 10.1371/journal.pone.0181065.

Delivery is key: lessons learnt from developing splice-switching antisense therapies.

Godfrey C, Desviat L, Smedsrod B, Pietri-Rouxel F, Denti M, Disterer P EMBO Mol Med. 2017; 9(5):545-557.

PMID: 28289078 PMC: 5412803. DOI: 10.15252/emmm.201607199.

References

Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D . The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol. 1998; 161(12):6871-7. View

Aartsma-Rus A, van Ommen G . Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA. 2007; 13(10):1609-24. PMC: 1986821. DOI: 10.1261/rna.653607. View

Ko J, Ma J . A rapid and efficient PCR-based mutagenesis method applicable to cell physiology study. Am J Physiol Cell Physiol. 2005; 288(6):C1273-8. DOI: 10.1152/ajpcell.00517.2004. View

Jensen L, Muzio M, Mantovani A, WHITEHEAD A . IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol. 2000; 164(10):5277-86. DOI: 10.4049/jimmunol.164.10.5277. View

Kurreck J . Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem. 2003; 270(8):1628-44. DOI: 10.1046/j.1432-1033.2003.03555.x. View

Smith D, Hanna R, Friend D, Moore H, Chen H, Farese A . The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003; 18(1):87-96. DOI: 10.1016/s1074-7613(02)00514-9. View

Malinowsky D, Lundkvist J, Laye S, Bartfai T . Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett. 1998; 429(3):299-302. DOI: 10.1016/s0014-5793(98)00467-0. View

Dinarello C . The many worlds of reducing interleukin-1. Arthritis Rheum. 2005; 52(7):1960-7. DOI: 10.1002/art.21107. View

Smeets R, Joosten L, Arntz O, Bennink M, Takahashi N, Carlsen H . Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 2005; 52(7):2202-11. DOI: 10.1002/art.21108. View

10.

Kole R, Krainer A, Altman S . RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012; 11(2):125-40. PMC: 4743652. DOI: 10.1038/nrd3625. View

11.

Smeets R, van de Loo F, Joosten L, Arntz O, Bennink M, Loesberg W . Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum. 2003; 48(10):2949-58. DOI: 10.1002/art.11234. View

12.

Jensen L, Whitehead A . Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell Signal. 2003; 15(8):793-802. DOI: 10.1016/s0898-6568(03)00039-1. View

13.

Jensen L, Whitehead A . The 3' untranslated region of the membrane-bound IL-1R accessory protein mRNA confers tissue-specific destabilization. J Immunol. 2004; 173(10):6248-58. DOI: 10.4049/jimmunol.173.10.6248. View

14.

Burger D, Chicheportiche R, Giri J, Dayer J . The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995; 96(1):38-41. PMC: 185170. DOI: 10.1172/JCI118045. View

15.

Gabay C, Smith M, Eidlen D, Arend W . Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997; 99(12):2930-40. PMC: 508145. DOI: 10.1172/JCI119488. View

16.

Symons J, Young P, Duff G . Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 1995; 92(5):1714-8. PMC: 42590. DOI: 10.1073/pnas.92.5.1714. View

17.

Raouane M, Desmaele D, Urbinati G, Massaad-Massade L, Couvreur P . Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem. 2012; 23(6):1091-104. DOI: 10.1021/bc200422w. View

18.

Huang J, Gao X, Li S, Cao Z . Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A. 1997; 94(24):12829-32. PMC: 24223. DOI: 10.1073/pnas.94.24.12829. View

19.

Mourich D, Iversen P . Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Curr Opin Mol Ther. 2009; 11(2):124-32. View

20.

Greene A, Puder M . Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg. 2003; 16(2):99-102. View